- Home
- WRLD vs RGNX Comparison
WRLD vs RGNX Comparison
Compare WRLD & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRLD
- RGNX
- Stock Information
- Founded
- WRLD 1962
- RGNX 2008
- Country
- WRLD United States
- RGNX United States
- Employees
- WRLD N/A
- RGNX N/A
- Industry
- WRLD Finance: Consumer Services
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WRLD Finance
- RGNX Health Care
- Exchange
- WRLD Nasdaq
- RGNX Nasdaq
- Market Cap
- WRLD 683.3M
- RGNX 661.2M
- IPO Year
- WRLD 1991
- RGNX 2015
- Fundamental
- Price
- WRLD $132.85
- RGNX $11.94
- Analyst Decision
- WRLD
- RGNX Strong Buy
- Analyst Count
- WRLD 0
- RGNX 7
- Target Price
- WRLD N/A
- RGNX $30.00
- AVG Volume (30 Days)
- WRLD 67.0K
- RGNX 586.7K
- Earning Date
- WRLD 10-23-2025
- RGNX 11-06-2025
- Dividend Yield
- WRLD N/A
- RGNX N/A
- EPS Growth
- WRLD N/A
- RGNX N/A
- EPS
- WRLD 10.75
- RGNX N/A
- Revenue
- WRLD $570,763,378.00
- RGNX $155,782,000.00
- Revenue This Year
- WRLD N/A
- RGNX $198.02
- Revenue Next Year
- WRLD $3.55
- RGNX $2.67
- P/E Ratio
- WRLD $12.36
- RGNX N/A
- Revenue Growth
- WRLD 2.33
- RGNX 74.95
- 52 Week Low
- WRLD $104.99
- RGNX $5.04
- 52 Week High
- WRLD $185.48
- RGNX $13.93
- Technical
- Relative Strength Index (RSI)
- WRLD 32.76
- RGNX 50.72
- Support Level
- WRLD $125.00
- RGNX $12.66
- Resistance Level
- WRLD $136.58
- RGNX $13.93
- Average True Range (ATR)
- WRLD 7.31
- RGNX 0.71
- MACD
- WRLD -3.57
- RGNX -0.17
- Stochastic Oscillator
- WRLD 15.46
- RGNX 20.48
About WRLD World Acceptance Corporation
World Acceptance Corp operates a small-loan consumer finance business. The company offers short-term small installment loans, medium-term larger installment loans, related credit insurance and ancillary products and services to individuals. It also offers income tax return preparation services to its loan customers and other individuals. The Company operates 1,024 branches in Alabama, Georgia, Idaho, Illinois, Indiana, Kentucky, Louisiana, Mississippi, Missouri, New Mexico, Oklahoma, South Carolina, Texas, Tennessee, Utah, and Wisconsin.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.